Caribou Biosciences reports today with options positioning at its most defensive reading of the past year.
The clearest pre-earnings signal is in the options market. The put/call ratio jumped to 0.44 on May 7 — the highest level recorded in the past 52 weeks, and well above its 20-day average of 0.27. That z-score of 1.56 reflects a meaningful shift toward downside protection in the days before the print. The stock closed at $1.88, down 3.6% on the day and flat on the week, having shed the same amount over the past month. Gene-editing peers moved in the same direction: EDIT fell 4.6% and CRSP dropped 4.8% on the session, suggesting broader sector pressure rather than a company-specific move.
Short interest, by contrast, does not tell an aggressive story. CRBU carries 7.4% of its free float short — meaningful for a clinical-stage biotech, but the position has been drifting lower. Short shares fell roughly 1.3% in a single day and are down about 2.4% over the past month. The lending market is loose: borrow availability is ample, with cost to borrow running near 0.60% — a fraction of the levels that would signal genuine squeeze pressure. The ORTEX short score of 53 sits roughly at mid-range, consistent with a moderately watched name rather than a crowded short.
The bull case rests squarely on clinical catalysts. Analysts who cover the name — six of them rated Buy, with a consensus target near $11.71 against a $1.88 price — point to CB-011's RMAT designation and its early efficacy profile in relapsed/refractory multiple myeloma as the key differentiators. Evercore raised its target to $13 in March after the last readout. Bears, meanwhile, are left with the structural reality of a cash-burning clinical-stage company: the EV/EBITDA and PE ratios are both deeply negative, and the stock has lost ground even as pipeline data has been constructive. The gap between the $1.88 price and analyst targets reflects just how wide the uncertainty band remains — those targets should be treated as blue-sky scenarios rather than near-term anchors.
Historical print reactions have been punishing. The November 2025 earnings event saw the stock fall 11.4% on the day and 18.8% over the following five days. The prior quarter delivered a more modest decline of 4.8%. The insider register offers one small counterpoint: CEO Rachel Haurwitz bought 20,000 shares in March 2025, and the 90-day net insider position is modestly positive — small in dollar terms but a directional signal from the top of the house.
Today's print is a test of whether the CB-011 data trajectory justifies the Street's persistent Buy consensus at a price that implies years of optionality are currently on sale.
See the live data behind this article on ORTEX.
Open CRBU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
